Patients With Renal Impairment Undergoing CT

Completed · Phase 4

Conditions studied: Contrast Induced Nephropathy

In brief

The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV contrast-enhanced (multidetector computed tomography) MDCT of the liver or MDCT angiography of the lower extremities. Serum Creatinine (SCr) will be measured before and up to 48-72 hours post dose.

Key facts

Study ID

NCT00292487

Run by

Bracco Diagnostics, Inc

People needed

150

Starts

2004-11-01

Expected to finish

2006-02-01

Last updated by the study team

2012-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• referred for MDCT of liver or peripheral CTA
• stable baseline SCr of 1.5 - 2.5 mg/dL and/or calculated CrCl of 10-60 mL/min

You may not qualify if…

• unstable renal function
• required prophylactic drugs to receive contrast (other than hydration)
• uncontrolled diabetes
• currently on dialysis

Where it is running

• Bracco Diagnostics, Inc — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.